Statement: There were 0 cases of night blindness in the primary trial, and 1 in the secondary trial.
Primary_evidence: Adverse Events 1:   Total: 19/3761 (0.51%)   Cardiac ischemia/infarction 3/3761 (0.08%)   Left ventricular systolic dysfunction 1/3761 (0.03%)   Restrictive cardiomyopathy 1/3761 (0.03%)   Supraven.arrhyth. Atrial flutter 1/3761 (0.03%)   Ventric.arrhyth. Trigeminy 1/3761 (0.03%)   Hypothyroidism 0/3761 (0.00%)   Blurred vision 1/3761 (0.03%)   Nyctalopia 0/3761 (0.00%)   Ocular - Other 1/3761 (0.03%) Adverse Events 2:   Total: 7/3759 (0.19%)   Cardiac ischemia/infarction 0/3759 (0.00%)   Left ventricular systolic dysfunction 0/3759 (0.00%)   Restrictive cardiomyopathy 0/3759 (0.00%)   Supraven.arrhyth. Atrial flutter 0/3759 (0.00%)   Ventric.arrhyth. Trigeminy 0/3759 (0.00%)   Hypothyroidism 1/3759 (0.03%)   Blurred vision 0/3759 (0.00%)   Nyctalopia 1/3759 (0.03%)   Ocular - Other 0/3759 (0.00%)
Secondary_evidence: Adverse Events 1:   Total: 29/48 (60.42%)   Anemia 4/48 (8.33%)   Febrile neutropenia 7/48 (14.58%)   Atrial fibrillation 1/48 (2.08%)   Pericardial effusion 1/48 (2.08%)   Sinus bradycardia 1/48 (2.08%)   Nausea 2/48 (4.17%)   Vomiting 2/48 (4.17%)   Death NOS 1/48 (2.08%)   Fatigue 3/48 (6.25%)   Allergic reaction 1/48 (2.08%)   Lung infection 1/48 (2.08%)   Mucosal infection 1/48 (2.08%)